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Craniofrontonasal syndrome (CFNS) is an X-linked craniofacial disorder with an unusual manifestation pattern,
in which affected females show multiple skeletal malformations, whereas the genetic defect causes no or only mild
abnormalities in male carriers. Recently, we have mapped a gene for CFNS in the pericentromeric region of the X
chromosome that contains the EFNB1 gene, which encodes the ephrin-B1 ligand for Eph receptors. Since Efnb1
mutant mice display a spectrum of malformations and an unusual inheritance reminiscent of CFNS, we analyzed
the EFNB1 gene in three families with CFNS. In one family, a deletion of exons 2–5 was identiﬁed in an obligate
carrier male, his mildly affected brother, and in the affected females. In the two other families, missense mutations
in EFNB1 were detected that lead to amino acid exchanges P54L and T111I. Both mutations are located in
multimerization and receptor-interaction motifs found within the ephrin-B1 extracellular domain. In all cases,
mutations were found consistently in obligate male carriers, clinically affected males, and affected heterozygous
females. We conclude that mutations in EFNB1 cause CFNS.
Introduction
Craniofrontonasal syndrome (CFNS [MIM 304110]), a
subgroup of craniofrontonasal dysplasia, is character-
ized by craniofacial asymmetry, hypertelorism, coronal
synostosis, strabismus, biﬁd nasal tip, grooved nails, and
abnormalities of the thoracic skeleton, as well as wiry
and curly hair. Rare manifestations are anterior cranium
biﬁdum, axillary pterygium, joint abnormalities, cleft lip
and palate, unilateral breast hypoplasia, asymmetric
lower-limb shortness, corpus callosum hypoplasia, um-
bilical hernia, and diaphragmatic hernia. CFNS shows
a very unusual pattern of X-linked inheritance, in which
most affected patients are females and obligate male car-
riers show no or only mild manifestation, such as hy-
pertelorism (Saavedra et al. 1996). Compagni et al.
(2003) reported that targeted inactivation of the X-
linked gene Efnb1 in mice causes partial perinatal le-
thality, abdominal wall closure defects, and skeletal ab-
normalities, especially of the thoracic cage. Interestingly,
the phenotype was more severe in female heterozygotes
than in hemizygous males, and some defects, such as
preaxial polydactyly, were only detected in heterozy-
gotes. The human homologue EFNB1 (MIM 300035)
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is localized at Xq12, within the mapping interval for
CFNS (DXS993/PFC–DXS1125/DXS8111) (Wieland et
al. 2002), making EFNB1 a striking candidate gene for
this syndrome. However, locus heterogeneity for CFNS
cannot be excluded, because previous linkage studies
suggested a localization of CFNS in Xp22 (Feldman et
al. 1997).
Subjects and Methods
Patients and Study Subjects
All members of the families included in this study gave
their informed consent to perform linkage and haplotype
analysis as well as to search for mutations in candidate
genes. The affected females exhibit typical features of
CFNS, including hypertelorism and craniofacial abnor-
malities, such as orbital asymmetry (ﬁg. 1). All affected
females of these three families are normal in their mental
performance and show no behavioral abnormalities.
Body height is also in the normal range for all affected
females.
The pedigree of family 1 is shown in ﬁgure 2A. In
patient III1, hypertelorism, biﬁd nasal tip, grooved nails,
axillary pterygium, and slight pterygium colli were ob-
served. In I2 and II6, hypertelorism and grooved nails
have been reported. The obligate male carrier (II3) and
his brother (II5) show only hypertelorism as a micro-
symptom of CFNS.
The pedigree of family 2 is shown in ﬁgure 3A. The
phenotypes of the patients include hypertelorism, orbital
asymmetry, brachycephaly, brachydactyly, and Sprengel
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Figure 1 Orbital asymmetry in a patient with CFNS
Figure 2 Family 1. A, Pedigree of family 1 with CFNS. B, De-
letion of the EFNB1 gene in family 1, detected by Southern blot anal-
ysis using exon 2 of the EFNB1 gene as a probe. C, PCR analysis of
exons 1–5 of EFNB1. Lane numbers refer to family members depicted
in the pedigree.
deformity. In III6, who experienced four miscarriages at
mid-pregnancy, uterus arcuatus has been detected. In
addition, III6 has curly hair as well as grooved ﬁnger
nails and unilateral breast hypoplasia. The obligate car-
rier male (III2) shows no phenotypic abnormalities. The
son (V3) of an affected female exhibits a broad nasal
bridge, with an inner canthel distance of 3.8 cm, at 9
years of age.
The pedigree of family 3 is shown in ﬁgure 4A. I1
shows a slight facial asymmetry and a broad nasal
bridge. In II1, severe facial asymmetry, hypertelorism,
and hypoplasia of corpus callosum were observed. Her
daughter (III2) exhibits facial asymmetry, hypertelorism,
agenesis of the corpus callosum, complete syndactyly of
the third and fourth ﬁnger on the left side, and scoliosis.
Her son (III1) exhibits no features of CFNS.
Genotyping, X-Inactivation Test, and Candidate Gene
Analysis
Haplotype analysis of families 1 and 3 with the use
of microsatellite markers from chromosome X was per-
formed as described elsewhere (Wieland et al. 2002). To
control for the pattern of X inactivation, the HUMAR
assay (Allen et al. 1992) was applied as described else-
where (Wieland et al. 2002). Deletion analysis of the
EFNB1 gene was performed by PCR with the use of
primers 5′-GGCAGAGGAAGGCGAGGCGA-3′ and 5′-
CAACCCAGCCAAGTGCCCCT-3′, which generated a
401-bp PCR product from exon 1; primers 5′-GGCTCT-
TGTCCGCTTCCCTG-3′ and 5′-AGAGGATGGGATG-
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Figure 3 Family 2.A, Part of the pedigree of family 2.B,Missense
mutation 1023CrT in exon 2 of EFNB1 in the hemizygous obligate
carrier male (III2) and in an affected heterozygous female. C, PCR anal-
ysis and RsaI restriction enzyme cleavage of exon 2 of EFNB1. Lane
numbers refer to family members depicted in the pedigree, and the frag-
ments carrying the mutation are indicated by an arrow.
GGCGG-3′, which generated a 386-bp PCR product
from exon 2; and primers 5′-GGGGAGCAGGCGTAG-
GGTTA-3′ and 5′-GCAAGGGGAGGGGGTGTG-3′,
which generated an 892-bp PCR product from exons 4
and 5. PCR products were analyzed by agarose gel elec-
trophoresis. For sequence analysis, PCR products were
isolated by gel extraction (QiaExII, Qiagen) and cloned
into vector pCR2.1, as recommended by the supplier
(Invitrogen). Plasmid preparations of single colonies
were analyzed by M13 sequencing on an automatic laser
ﬂuorescent (ALF) express sequencer (Pharmacia). At
least two independent clones were sequenced. For direct
patient-DNA sequencing, Cy5-labeled exon-speciﬁc
EFNB1 primers were used (table 1 [online only]). Stan-
dard sequencing reactions were performed using a kit
(Amersham-Biotech) and were resolved on an ALF ex-
press sequencer (Pharmacia). Sequences were analyzed
by DNAsis (Hitashi).
For analysis of DNA from normal controls and from
family members of the pedigrees, standard PCRwas per-
formed using primers for exon 2 of the EFNB1 gene, as
described above. The PCR products were digested with
BslI (New England BioLabs) to control for 862TrC.
PCR products from the wild type generated fragments
of 24 bp, 97 bp, 126 bp, and 139 bp. PCR products
containing 862TrC generated fragments of 24 bp, 126
bp, and 236 bp. To control for missense mutation
1023TrC, PCR products from exon 2 were reampliﬁed
with the use of primers 5′-CCTGCAATAGGCCAGAG-
CAGGAAATACGCTGT-3′, which introduces an RsaI
restriction-enzyme site speciﬁcally at 1023T, and 5′-
GGATGGGATGGGCGGGACTCACAG-3′. PCR and
cleavage products were analyzed on 3% agarose gels.
Southern Blot Hybridization
High molecular-weight patient DNAwas cleaved with
restriction endonuclease PstI (New England BioLabs).
The digests were resolved on an 0.8% agarose gel and
were blotted on Nylon membrane (Hybond-N, Amer-
sham Biosciences). Hybridization probes for EFNB1
exon 2 were prepared from PCR products (described
above) and were radiolabeled by random priming using
a[32P] dCTP. Hybridization, washings, and autoradio-
graphy were performed in accordance with standard
protocols (Sambrook et al. 1989).
Results
Haplotype analysis in family 1 (ﬁg. 2A), with the use of
18 informative, polymorphic DNA markers, conﬁrmed
our previous mapping interval in the pericentromeric
region of the X chromosome that contains the EFNB1
gene. The EFNB1 gene comprises 13.17 kb and 5 exons
(LocusLink accession number 1947; Ensembl accession
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Figure 4 Family 3. A, Part of the pedigree of family 3. B, Mis-
sense mutation 862CrT in the hemizygous affected male (I1) and in
a heterozygous affected female (III2) of pedigree 3. C, PCR-based
detection of the 862CrT mutation in family 3. Lane numbers refer
to family members depicted in the pedigree, and the fragments carrying
the mutation are indicated by an arrow.
number ENSP00000204961). In this family, a deletion
of exons 2–5 of the EFNB1 gene was detected in the
obligate male carrier (II3) and in his mildly affected
brother (II5) by PCR and Southern blot analysis (ﬁg. 2B
and 2C). The distal deletion breakpoint was located be-
tween markers RH65456 and DXS981, suggesting a de-
letion of a minimum 29 kb and a maximum 148 kb.
Although exon 1 is not deleted, production of a func-
tional protein from this allele is not expected, since exon
1 merely encodes the signal peptide and 13 additional
amino acids of the ephrin-B1 protein. Deletion of exon
2 was not detected in 100 male controls analyzed by
PCR (data not shown). Semiquantitative Southern blot
analysis, with the use of exon 2 of the EFNB1 gene as
hybridization probe, revealed half the gene dosage in the
affected females, compared with unaffected female
relatives (ﬁg. 2B).
In family 2 (ﬁg. 3A), DNA sequencing of the coding
region of exons 1–5 of the EFNB1 gene revealed the
hemizygous missense mutation 1023CrT (with the use
of EFNB1 reference sequence [GenBank accession num-
ber XM_038809]) in exon 2 in the obligate male carrier,
III2 (ﬁg. 3B). All affected females in this family were
heterozygous for 1023CrT. Furthermore, a heterozy-
gous female’s son (V3), clinically identiﬁed as an af-
fected male because of hypertelorism, also carries this
mutation (ﬁg. 3C).
In family 3 (ﬁg. 4A), mapping information for the
CFNS locus was not available, because haplotype anal-
ysis was not informative (data not shown). The carrier
male (I1) harbored the missense mutation 862CrT in
exon 2 (ﬁg. 4B) and the two affected females (II1 and
III2) were heterozygous (ﬁg. 4C). Both of the identiﬁed
missense mutations have not been recorded as allele
variants in the databases (GenBank and dbSNP) and
were not detected in 150 control X chromosomes (data
not shown). 1023CrT replaces Thr 111 with Ile, and
862CrT replaces Pro 54 with Leu, in the extracellular
domain of ephrin-B1 (ﬁg. 5A). Both Thr 111 and Pro
54 are highly conserved in the three known ephrin-B
ligands and across a great variety of species (ﬁg. 5B).
Therefore, we assume that both mutations will com-
promise the biological activity of ephrin-B1. In all af-
fected females of the three families, no skewed inacti-
vation of the X chromosome was detected by the
HUMAR assay (data not shown).
Discussion
Ephrin ligands and Eph-receptor tyrosine kinases are
versatile regulators of embryonic tissue morphogenesis,
with known functions in many tissues and organ systems
(Wilkinson 2001; Kullander and Klein 2002). The eight
known ephrin-ligands are divided into the ephrin-A
ligands (EFNA1–A5), which are membrane anchored by
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Figure 5 EFNB1 protein and ephrin-B conservation. A, Position of EFNB1 missense mutations that cause CFNS. The mutations are
shown on the primary sequence of EFNB1 protein with its signal peptide (SP), transmembrane domain (TM), and cytoplasmic domain (CY).
Both missense mutations are located in the ephrin extracellular domain. Deletion Dexon 2–5 is indicated at the cDNA level. B, Evolutionary
conservation of P54 and T111 in the ephrin-B class. Domains containing P54 (left column of amino acids) and T111 at the G-H loop (Himanen
et al. 2001; Toth et al. 2001) (right column of amino acids) of human EFNB1-B3 and of EFNB1 protein from mouse (m), rat (r), chicken (c),
frog (X), and zebraﬁsh (Dr) are shown.
a glycosylphosphatidylinositol linkage, and ephrin-B
ligands (EFNB1–B3), which are transmembrane pro-
teins. The 14 known ephrin-receptors in vertebrates can
be divided into two subclasses, EphA and EphB recep-
tors, depending on their preferential afﬁnity to ephrin-
A or ephrin-B proteins (Kullander and Klein 2002).
EphB receptors signal in combination with B-class
ephrins to control the patterning of the developing skel-
eton, the nervous system, the intestine, and the blood
vessels. It is noteworthy that ephrins not only function
as ligands but also exhibit receptor-like effects (Wilkin-
son 2001). The Eph/ephrin transduction system plays a
role in the guidance of neuronal growth and cell migra-
tion, mainly by providing repulsive signals (Murai and
Pasquale 2003).
Ephrin-B1 mutant mice display malformations of the
axial and appendicular skeleton, such as asymmetric
attachment of ribs, lack of joints, and polydactyly. These
defects have been attributed to missing or ectopic seg-
mentation of mesenchymal condensations during early
steps of skeletal development (Compagni et al. 2003).
Patients with CFNS show striking asymmetry of cran-
iofacial structures and other skeletal malformations.
Abnormalities of the thoracic skeleton in CFNS include
Sprengel deformity, clavicle pseudoarthrosis, pectus ex-
cavatum, and disorders of ribs and sternum that are
similar to the defects observed in ephrin-B1 knockout
mice. Other CNFS features are midline defects, includ-
ing anterior cranium biﬁdum, corpus callosum hypo-
plasia, cleft lip and palate, omphalocele, and dia-
phragma hernia. In this context, it is interesting that,
in family 2, one affected female who had four miscar-
riages at mid-pregnancy exhibits a uterus arcuatus. This
malformation, caused by a failure of the fusion of the
Mu¨llerian derivatives, would explain the higher risk of
abortion observed in some women affected by CFNS
(Devriendt et al. 1995). Many of these malformations
show signiﬁcant similarity to malformations in mice
lacking ephrin-B1 or EphB receptors (Henkemeyer et
al. 1996; Orioli et al. 1996; Compagni et al. 2003).
Our results demonstrate unambiguously that muta-
tions of EFNB1 cause CFNS. At the molecular level,
deletion of the EFNB1 gene in family 1 is most similar
to target inactivation of Efnb1 in the mouse. Missense
mutations T111I and P54L in the two other families
appear to abrogate ephrin-B1–Eph receptor binding.
Elsewhere, crystal-structure analysis of the highly re-
lated ephrin-B2 ligand showed that the corresponding
Thr of ephrin-B2 is one of the crucial residues at the
G-H loop involved in ligand dimerization and Eph re-
ceptor binding (Himanen et al. 2001; Toth et al. 2001).
These processes are thought to be highly relevant for
interactions with Eph receptors and signaling processes,
which can be blocked by mimetic peptides of the ephrin
G-H loop (Koolpe et al. 2002).
The unusual pattern of manifestation of CFNS—mul-
tiple skeletal malformations in affected females and no
or mild malformations in male carriers—may be ex-
plained by the promiscuity of ephrin receptors and their
ligands and as the consequence of randomX inactivation
in females. The EFNB1 gene is subjected to X inacti-
vation (Carrel et al. 1999), and there is no evidence for
a homologous gene on the Y chromosome (LocusLink).
The HUMAR assay, performed on lymphocyte DNA of
all affected females of the three families, revealed a ran-
dom X inactivation. Furthermore, Compagni et al.
(2003) have shown that Efnb1 mutant female mice are
mosaic for Efnb1-positive and Efnb1-negative cell
clones. These experimental data and the clinical obser-
vations of the marked phenotype in heterozygotes and
of the absent or mild manifestation in hemizygotes
strongly support the idea that a skewed X inactivation
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is not the cause of the sex-dependent manifestation of
this syndrome. In fact, we expect that a random X in-
activation has an implication for the manifestation of
CFNS. Because ephrins are expressed in a complex, spa-
tially and temporally dynamic pattern during embryo-
genesis, we assume that, in heterozygous females,
ephrin-B1–expressing and ephrin-B1–deﬁcient cells lead
to divergent cell sorting andmigration. This disturbance
could be more pronounced in the contact areas of
EFNB1-positive and EFNB1-negative cells. In contrast
to the heterogeneous cell populations of heterozygotes,
hemizygosity is characterized by a homogeneous cell
population, in which ephrin-B1 may be replaced func-
tionally by another B-class ephrin. This model is rem-
iniscent of the concept of metabolic interference that
has been proposed on theoretic grounds by Johnson
(1980). Accordingly, the interaction of a mutant and a
normal allele would lead to a more severe disturbance
than the mutant allele alone. However, we propose the
term “cellular interference” for what occurs between
EphB-receptor–positive migrating cells and the two
kinds of cell populations in heterozygotes, that is, cells
with the active mutant X chromosome and cells with
the active wild-type X chromosome. The experiments
of Compagni et al. (2003) support this concept. Using
the X-green ﬂuorescence protein transgene for visuali-
zation of cells with the active wild-type X chromosome,
they showed that ephrin-B1–positive and ephrin-B1–
negative cells are organized in compartments by a ran-
dom X inactivation. These compartments obviously ex-
hibit different attractive impulses for invading EphB-
receptor–positive cells.
In summary, we have demonstrated that mutations
of EFNB1 cause CFNS. For the ﬁrst time, it can be
shown that mutations of the ephrin receptor/ephrin sig-
nal transduction system are associatedwith aMendelian
disorder and that ephrin signaling is involved in human
skeletal development. Finally, we propose an expla-
nation of the sex-dependent manifestation of CFNS.
The question of whether mutations in other ephrins,
in their receptors, or in members of the signaling cas-
cade may cause syndromes related to CFNS needs to
be investigated.
Acknowledgments
We thank the patients and their families for their partici-
pation. We thank J. Meyer, S. Engelberg, I. Frommelt, G. Koch,
and S. Schlenzka for technical assistance. This work was sup-
ported in part by a grant of the BMBF (NBL3).
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
Ensembl Genome Server, http://www.ensembl.org (for EFNB1
[accession number ENSP00000204961])
GenBank, http://www.ncbi.nlm.nih.gov/Genbank (for EFNB1
reference sequence [accession number XM_038809])
LocusLink, http://www.ncbi.nlm.nih.gov/LocusLink (for
EFNB1 [accession number 1947])
NCBI Molecular Variation Database (dbSNP), http://www
.ncbi.nlm.nih.gov/SNP
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim
References
Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont
JW (1992) Methylation of the HpaII and HhaI sites near
the polymorphic CAG repeat in the human androgen-
receptor gene correlates with X chromosome inactivation.
Am J Hum Genet 51:1229–1239
Carrel L, Cottle A, Goglin KC, Willard HF (1999) A ﬁrst-
generation X-inactivation proﬁle of the human X chromo-
some. Proc Natl Acad Sci 96:14440–14444
Compagni A, Logan M, Klein R, Adams R (2003) Control of
skeletal patterning by EphrinB1-EphB interactions. Dev Cell
5:217–230
Devriendt K, van Mol C, Fryns JP (1995) Craniofacial dys-
plasia: a more severe expression in the mother than in her
son. Genet Couns 6:361–364
Feldman GJ, Ward DE, Lajeunie-Renier E, Saavedra D, Robin
NH, Proud V, Robb LJ, Der Kaloustian V, Carey JC, Cohen
M, Cornier V, Munnich A, Zackai EH, Wilkie AOM, Price
RA, Muenke M (1997) A novel phenotypic pattern in X-
linked inheritance: craniofrontonasal syndrome maps to
Xp22. Hum Mol Genet 6:1937–1941
Henkemeyer M, Orioli D, Henderson JT, Saxton TM, Roder
J, Pawson T, Klein R (1996) Nuk controls pathﬁnding of
commissural axons in the mammalian central nervous sys-
tem. Cell 86:35–46
Himanen J-P, Rajashankar KR, Lackmann M, Cowan CA,
Henkemeyer M, Nikolov DB (2001) Crystal structure of an
Eph receptor-ephrin complex. Nature 414:933–938
Johnson WG (1980) Metabolic interference and -heterozy-
gote: a hypothetical form of simple inheritance which is
neither dominant nor recessive. Am J Hum Genet 32:374–
386
Koolpe M, Dail M, Pasquale EB (2002) An ephrin mimetic
peptide that selectively targets the EphA2 receptor. J Biol
Chem 277:46974–46979
Kullander K, Klein R (2002) Mechanisms and functions of
Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475–
486
Murai KK, Pasquale EB (2003) “Eph”ective signaling: for-
ward, reverse and crosstalk. J Cell Science 116:2823–2832
Orioli D, Henkemeyer M, Lemke G, Klein R, Pawson T (1996)
Sek4 and Nuk receptors cooperate in guidance of commis-
sural axons and in palate formation. EMBO J 15:6035–
6049
Saavedra D, Richieri-Costa A, Guion-Almeida ML, Cohen M
(1996) Craniofrontonasal syndrome: study of 41 patients.
Am J Med Genet 61:147–151
Wieland et al.: Mutations of EFNB1 Cause CFNS 1215
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning:
a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, NY
Toth J, Cutforth T, Gelinas AD, Bethoney KA, Bard J, Harrison
CJ (2001) Crystal structure of an ephrin ectodomain. Dev
Cell 1:83–92
Wieland I, Jakubiczka S, Muschke P, Wolf A, Gerlach L, Kraw-
czak M, Wieacker P (2002) Mapping of a further locus for
X-linked craniofrontonasal syndrome. Cytogenet Genome
Res 99:285–288
Wilkinson DG (2001) Multiple roles of EPH receptors and
ephrins in neural development. Nat Rev Neurosci 2:155–164
